MedTrace Logo

Bioactive Glass in the Treatment of Enamel White Spot Lesions

NCT04401280 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-10-19

No results posted yet for this study

Summary

the aim of this study is to evaluate the effectiveness of BiominF® and Novamin® in comparison to Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) in the treatment of enamel white spot lesions

Conditions

  • White Spot Lesion of Tooth

Interventions

DRUG

BiominF

in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached

DRUG

Novamin

in office application of bioactive glass followed by self administered application by the patient until a point of white spot remineralization is reached

DRUG

CPP-ACP

applied in accordance with the manufacturer's specifications

Sponsors & Collaborators

  • Queen Mary University of London

    collaborator OTHER

  • Rania Salah

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
26 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-06-30
Completion
2021-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04401280 on ClinicalTrials.gov